Co-morbidities in severe asthma: Clinical impact and management

TY - JOUR

T1 - Co-morbidities in severe asthma

T2 - Clinical impact and management

AU - Porsbjerg, Celeste

AU - Menzies-Gow, Andrew

N1 - © 2017 Asian Pacific Society of Respirology.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Patients with severe asthma represent a minority of the total asthma population, but carry a majority of the morbidity and healthcare costs. Achieving better asthma control in this group of patients is therefore of key importance. Systematic assessment of patients with possible severe asthma to identify treatment barriers and triggers of asthma symptoms, including co-morbidities, improves asthma control and reduces healthcare costs and is recommended by international guidelines on management of severe asthma. This review provides the clinician with an overview of the prevalence and clinical impact of the most common co-morbidities in severe asthma, including chronic rhinosinusitis, nasal polyposis, allergic rhinitis, dysfunctional breathing, vocal cord dysfunction, anxiety and depression, obesity, obstructive sleep apnoea syndrome (OSAS), gastroesophageal reflux disease (GERD), bronchiectasis, allergic bronchopulmonary aspergillosis (ABPA) and eosinophilic granulomatous with polyangiitis (EGPA). Furthermore, the review offers a summary of recommended diagnostic and management approaches for each co-morbidity. Finally, the review links co-morbid conditions to specific phenotypes of severe asthma, in order to guide the clinician on which co-morbidities to look for in specific patients.

AB - Patients with severe asthma represent a minority of the total asthma population, but carry a majority of the morbidity and healthcare costs. Achieving better asthma control in this group of patients is therefore of key importance. Systematic assessment of patients with possible severe asthma to identify treatment barriers and triggers of asthma symptoms, including co-morbidities, improves asthma control and reduces healthcare costs and is recommended by international guidelines on management of severe asthma. This review provides the clinician with an overview of the prevalence and clinical impact of the most common co-morbidities in severe asthma, including chronic rhinosinusitis, nasal polyposis, allergic rhinitis, dysfunctional breathing, vocal cord dysfunction, anxiety and depression, obesity, obstructive sleep apnoea syndrome (OSAS), gastroesophageal reflux disease (GERD), bronchiectasis, allergic bronchopulmonary aspergillosis (ABPA) and eosinophilic granulomatous with polyangiitis (EGPA). Furthermore, the review offers a summary of recommended diagnostic and management approaches for each co-morbidity. Finally, the review links co-morbid conditions to specific phenotypes of severe asthma, in order to guide the clinician on which co-morbidities to look for in specific patients.

KW - Aspergillosis, Allergic Bronchopulmonary/epidemiology

KW - Asthma/epidemiology

KW - Bronchiectasis/epidemiology

KW - Chronic Disease

KW - Comorbidity/trends

KW - Disease Management

KW - Gastroesophageal Reflux/epidemiology

KW - Global Health

KW - Humans

KW - Rhinitis, Allergic/epidemiology

KW - Sleep Apnea, Obstructive/epidemiology

U2 - 10.1111/resp.13026

DO - 10.1111/resp.13026

M3 - Review

C2 - 28328160

SN - 1323-7799

VL - 22

SP - 651

EP - 661

JO - Respirology

JF - Respirology

IS - 4

ER -